

REMARKS

This preliminary amendment is being filed to correct an obvious typographical error in a column heading in Table 4. Applicants submit that no new matter has been added by this amendment.

Applicants submit that correction of the typographical error in the column heading in the Table does not constitute new matter because the strain listed in the Table that was inadvertently labeled as "BR020" was intended to be a clade A strain as indicated on the Table by "(A)" in the as-filed specification. BR020 is a clade F strain while RW020 is a clade A strain (see WHO Network for HIV Isolation and Characterization (1994) AIDS Res. Hum. Retroviruses 10, 1359). In addition, as indicated in the specification, virus pseudotyped with the envelope strain in question was tested for neutralization by sera from clade A virus infected individuals but not by sera from clade F virus infected individuals (see page 26, line 15 through page 27, line 2). The neutralization testing scheme that was used to generate the data in Table 4 would have been illogical for a clade F envelope strain because the BR020 clone is minimally positive for functional activity using the assay employed in Table 4. This level of minimal functional activity would not have permitted its use in the assays disclosed in the specification. The RW020 clone, however, is highly functional under these conditions and therefore used in Applicants' experiments, and was intended to be listed on Table 4 as indicated in this Amendment.


Conclusion

Attached hereto is a marked-up version of the changes made to the Table in the specification by the current amendment. The attached page is captioned Version with markings to show changes made.

If there are any fees due in connection with the filing of this Amendment, please charge the fees to our Deposit Account No. 50-0310. If a fee is required for an extension of time under 37 C.F.R. 1.136 not accounted for, such an extension is requested and the fee should also be charged to our Deposit Account.

Dated: **January 30, 2002**
Morgan, Lewis & Bockius LLP
Customer No. **09629**
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
202-739-3000

Respectfully submitted
Morgan, Lewis & Bockius LLP



Robert Smyth
Registration No. P50,801

VERSION WITH MARKINGS TO SHOW CHANGES MADE

Table 4 on pages 34-35 has been amended as follows:

Table 4. Neutralization of Pseudoviruses Expressing Envelopes of Various Clades by Sera from People Infected with Various Clades of HIV-1

Clade	Serum ^b	NA Titer Against Pseudovirus (Clade) ^a							
		R2	P9	P10	BR020 RW020	MW965	Z2Z6	TH966	UG975
		(B)	(B)	(B)	(A)	(C)	(D)	(E)	(G)
B	Ref 1	32	16	32	<10	256	10	<8	<10
	Ref 2	64	32	64	10	128	40	8	10
	WR8465	20	NT ^c	80	<10	640	10	<10	10
A	37570	320	160	20	80	2560	<10	<10	<10
	35374	40	<10	<10	<10	640	<10	<10	<10
	35837	40	20	<10	80	2560	<10	<10	<10
C	5107	40	10	<10	10	1280	<10	<10	<10
	5708	10	<10	<10	<10	320	<10	<10	<10
	5218	80	<10	<10	<10	1280	<10	<10	<10
D	UG9240	<10	NT	NT	NT	NT	NT	20	NT
	UG9370	<10	NT	NT	NT	NT	NT	10	NT
	UG9386	<10	NT	NT	NT	NT	NT	10	NT
	UG93097	10	NT	NT	NT	NT	NT	10	NT
	UG94118	10	NT	NT	NT	NT	NT	20	NT
E	WR5659	10	<10	<10	<10	20	<10	40	<10
	WR5901	<10	<10	<10	40	320	10	40	10
	WR8177	<10	<10	<10	40	640	10	80	<10
	WR8657	<10	<10	10	10	640	<10	80	<10
	WR8593	<10	<10	<10	<10	160	10	40	<10
	1008	<10	<10	<10	<10	10	<10	<10	<10
	1053	20	<10	<10	<10	40	<10	20	<10
F	1062	20	10	<10	10	320	<10	20	<10
	BR9318	<10	NT	NT	NT	NT	NT	<10	NT
	BR93019	10	NT	NT	NT	NT	NT	<10	NT
	BR93020	20	NT	NT	NT	NT	NT	<10	NT
	BR93029	10	NT	NT	NT	NT	NT	<10	NT